MedTrace Logo

A Study to Determine the Absorption of Peroral Insulin in Dextran Matrix (ORA3)

NCT01114750 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2010-10-05

No results posted yet for this study

Summary

A pharmacokinetic study on the absorption of perorally delivered insulin in dextran matrix after single dose administration.

Conditions

Interventions

DRUG

Insulin in dextran matrix capsule (and placebo)

Single dose capsule (and placebo)

Sponsors & Collaborators

  • Bows Pharmaceuticals AG

    lead INDUSTRY

Principal Investigators

  • Nabil Al-Tawil, M.D.; Ph.D. · Karolinska Trial Alliance, Stockholm

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-08-31
Completion
2010-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01114750 on ClinicalTrials.gov